{
  "id": "329719f3-4d59-4885-99ea-4ce292da41ab",
  "title": "Vision: protecting and restoring a prized sense",
  "link": "https://www.nature.com/articles/d41586-025-00653-8",
  "description": "",
  "author": "Richard Hodson",
  "published": "2025-03-05",
  "source": "https://www.nature.com/nature.rss",
  "categories": null,
  "byline": "Hodson, Richard",
  "length": 5598,
  "excerpt": "The scale of work to improve therapies for eye disease reflects the importance people place on sight. The scale of work to improve therapies for eye disease reflects the importance people place on sight.",
  "siteName": "",
  "favicon": "https://www.nature.com/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
  "text": "OUTLOOK 05 March 2025 The scale of work to improve therapies for eye disease reflects the importance people place on sight. Richard Hodson Credit: Sam Falconer for NatureHumans are endowed with a powerful suite of senses. Most people experience the world through sound, smell, touch, taste, temperature and pain, but it is vision that is valued the highest. A 2016 survey of adults in the United Kingdom found that, on average, people would rather live for 4.6 years with perfect health than for 10 years without sight (J. Enoch et al. JAMA Ophthalmol. 137, 1317–1320; 2019). Just think about that for a moment: these mostly healthy, wealthy adults were willing to trade more than five years of life for their sight. It’s a statistic that captures the importance of vision, but also the fear that often accompanies the idea of losing it. Nature Outlook: VisionWith such strong feelings on display, the scale of work being done to prevent and treat sight loss should be no surprise. Therapies for age-related macular degeneration (AMD), the most common cause of blindness in people over 50, are developing apace. For the advanced form known as geographic atrophy, the arrival of progression-slowing drugs in 2023 was a watershed moment. Improved options could well follow, including cell therapies. AMD treatment typically requires frequent injections directly into the eyeball — an uncomfortable status quo that gene therapy might upend.For people who have already lost their sight, neuroscientist Lore Thaler at Durham University, UK, thinks that echolocation should be widely taught to help improve their quality of life. And for those with the genetic disorder retinitis pigmentosa, clinical trials of optogenetic techniques to restore vision are, sometimes, exceeding even their developers’ expectations. There is also progress in the prevention of vision disorders. Early diagnosis of eye conditions, powered by artificial intelligence, might be finally coming of age as the technology is rolled out in earnest in India and Thailand. And circling far above our heads, efforts are being made to address one of NASA’s ‘red risks’ for long-term space flight and prevent astronauts aboard the International Space Station from losing their sight. Whether at home or in space, eye health is clearly a priority.We are pleased to acknowledge the financial support of Astellas Pharma in producing this Outlook. As always, Nature retains sole responsibility for all editorial content. Nature 639, S1 (2025) doi: https://doi.org/10.1038/d41586-025-00653-8This article is part of Nature Outlook: Vision, a supplement produced with financial support from Astellas Pharma. Nature maintains full independence in all editorial decisions related to the content. About this content. Related Articles Eye problems cloud NASA’s vision of Mars How can treatment for eye disease be made easier? Restoring vision with optogenetics Human echolocation can be taught Artificial intelligence could boost eye care in low-income countries The search for solutions to geographic atrophy of the retina Sponsor feature: The hunt for cell and gene therapies for eye diseases Subjects Latest on:",
  "image": "https://media.nature.com/lw1200/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50710514.jpg",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-container-type=\"article\" data-component=\"article-container\" id=\"content\"\u003e\n        \n            \n                \n            \n        \n\n        \n            \n        \n        \n            \n                \u003cmain\u003e\n                    \u003carticle data-track-component=\"news\" lang=\"en\"\u003e\n                        \n\u003cdiv\u003e\n    \u003cheader\u003e\n        \u003cdiv\u003e\n            \u003cul data-test=\"article-identifier\"\u003e\n                \u003cli data-test=\"article-category\"\u003e\u003cspan\u003eOUTLOOK\u003c/span\u003e\u003c/li\u003e\n                \u003cli\u003e\u003ctime datetime=\"2025-03-05\"\u003e05 March 2025\u003c/time\u003e\u003c/li\u003e\n                \n            \u003c/ul\u003e\n\n            \n\n            \u003cdiv\u003e\n                \n                \u003cp\u003e\n                    The scale of work to improve therapies for eye disease reflects the importance people place on sight.\n                \u003c/p\u003e\n            \u003c/div\u003e\n        \u003c/div\u003e\n        \n            \u003cdiv data-test=\"author-info\"\u003e\n    \u003col\u003e\n        \n            \u003cli\u003e\n                \n                    \u003cspan\u003eRichard Hodson\u003c/span\u003e\n                \n                \n                \n                    \n                \n            \u003c/li\u003e\n        \n    \u003c/ol\u003e\n\u003c/div\u003e\n        \n    \u003c/header\u003e\n    \n\u003c/div\u003e\n\n            \n            \n\n\n        \n            \n                \n                    \n                        \n\n                        \n                            \n                        \n                    \n                \n            \n\n            \n                \n                \u003cdiv\u003e\n                    \n                        \u003cfigure\u003e\u003cpicture\u003e\u003csource type=\"image/webp\" srcset=\"https://media.nature.com/lw767/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50710510.jpg?as=webp 767w, https://media.nature.com/lw319/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50710510.jpg?as=webp 319w\" sizes=\"(max-width: 319px) 319px, (min-width: 1023px) 100vw,  767px\"/\u003e\u003cimg alt=\"An illustration of an ey pupil made of colourful visuals and immaginary items.\" loading=\"lazy\" src=\"https://media.nature.com/lw767/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50710510.jpg\"/\u003e\u003cfigcaption\u003e\u003cp\u003e\u003cspan\u003eCredit: Sam Falconer for\u003ci\u003e Nature\u003c/i\u003e\u003c/span\u003e\u003c/p\u003e\u003c/figcaption\u003e\u003c/picture\u003e\u003c/figure\u003e\u003cp\u003eHumans are endowed with a powerful suite of senses. Most people experience the world through sound, \u003ca href=\"https://www.nature.com/collections/hcjfdcbgaj\" data-track=\"click\" data-label=\"https://www.nature.com/collections/hcjfdcbgaj\" data-track-category=\"body text link\"\u003esmell\u003c/a\u003e, touch, \u003ca href=\"https://www.nature.com/collections/yytphfnsjs\" data-track=\"click\" data-label=\"https://www.nature.com/collections/yytphfnsjs\" data-track-category=\"body text link\"\u003etaste\u003c/a\u003e, temperature and pain, but it is vision that is valued the highest. A 2016 survey of adults in the United Kingdom found that, on average, people would rather live for 4.6 years with perfect health than for 10 years without sight (\u003ca href=\"https://doi.org/10.1001/jamaophthalmol.2019.3537\" data-track=\"click\" data-label=\"https://doi.org/10.1001/jamaophthalmol.2019.3537\" data-track-category=\"body text link\"\u003eJ. Enoch \u003ci\u003eet al. JAMA Ophthalmol\u003c/i\u003e. \u003cb\u003e137\u003c/b\u003e, 1317–1320; 2019\u003c/a\u003e). Just think about that for a moment: these mostly healthy, wealthy adults were willing to trade more than five years of life for their sight. It’s a statistic that captures the importance of vision, but also the fear that often accompanies the idea of losing it. \u003c/p\u003e\u003carticle data-label=\"Related\"\u003e\u003ca href=\"https://www.nature.com/collections/cedgfdjgjd\" data-track=\"click\" data-track-label=\"recommended article\"\u003e\u003cimg alt=\"\" src=\"https://media.nature.com/w400/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709302.jpg\"/\u003e\u003cp\u003eNature Outlook: Vision\u003c/p\u003e\u003c/a\u003e\u003c/article\u003e\u003cp\u003eWith such strong feelings on display, the scale of work being done to prevent and treat sight loss should be no surprise. Therapies for age-related macular degeneration (AMD), the most common cause of blindness in people over 50, are developing apace. For the advanced form known as geographic atrophy, the arrival of progression-slowing drugs in 2023 was a watershed moment. Improved options could well follow, including \u003ca href=\"https://www.nature.com/articles/d41586-025-00659-2\" data-track=\"click\" data-label=\"https://www.nature.com/articles/d41586-025-00659-2\" data-track-category=\"body text link\"\u003ecell therapies\u003c/a\u003e. AMD treatment typically requires frequent injections directly into the eyeball — an uncomfortable status quo that \u003ca href=\"https://www.nature.com/articles/d41586-025-00655-6\" data-track=\"click\" data-label=\"https://www.nature.com/articles/d41586-025-00655-6\" data-track-category=\"body text link\"\u003egene therapy might upend\u003c/a\u003e.\u003c/p\u003e\u003cp\u003eFor people who have already lost their sight, neuroscientist Lore Thaler at Durham University, UK, thinks that \u003ca href=\"https://www.nature.com/articles/d41586-025-00657-4\" data-track=\"click\" data-label=\"https://www.nature.com/articles/d41586-025-00657-4\" data-track-category=\"body text link\"\u003eecholocation should be widely taught\u003c/a\u003e to help improve their quality of life. And for those with the genetic disorder retinitis pigmentosa, clinical trials of optogenetic techniques to restore vision are, sometimes, \u003ca href=\"https://www.nature.com/articles/d41586-025-00656-5\" data-track=\"click\" data-label=\"https://www.nature.com/articles/d41586-025-00656-5\" data-track-category=\"body text link\"\u003eexceeding even their developers’ expectations\u003c/a\u003e. There is also progress in the prevention of vision disorders. Early diagnosis of eye conditions, powered by artificial intelligence, \u003ca href=\"https://www.nature.com/articles/d41586-025-00658-3\" data-track=\"click\" data-label=\"https://www.nature.com/articles/d41586-025-00658-3\" data-track-category=\"body text link\"\u003emight be finally coming of age\u003c/a\u003e as the technology is rolled out in earnest in India and Thailand. And circling far above our heads, efforts are being made to address \u003ca href=\"https://www.nature.com/articles/d41586-025-00654-7\" data-track=\"click\" data-label=\"https://www.nature.com/articles/d41586-025-00654-7\" data-track-category=\"body text link\"\u003eone of NASA’s ‘red risks’ for long-term space flight\u003c/a\u003e and prevent astronauts aboard the International Space Station from losing their sight. Whether at home or in space, eye health is clearly a priority.\u003c/p\u003e\u003cp\u003eWe are pleased to acknowledge the financial support of Astellas Pharma in producing this Outlook. As always, \u003ci\u003eNature\u003c/i\u003e retains sole responsibility for all editorial content.\u003c/p\u003e\n                    \n                \u003c/div\u003e\n            \n                \u003cp\u003e\u003cem\u003eNature\u003c/em\u003e \u003cstrong\u003e639\u003c/strong\u003e, S1 (2025)\u003c/p\u003e\n                \u003cp\u003e\u003cem\u003edoi: https://doi.org/10.1038/d41586-025-00653-8\u003c/em\u003e\u003c/p\u003e\u003cdiv\u003e\u003cp\u003eThis article is part of \u003ca href=\"https://www.nature.com/collections/cedgfdjgjd\" data-track=\"click\" data-label=\"https://www.nature.com/collections/cedgfdjgjd\" data-track-category=\"body text link\"\u003eNature Outlook: Vision\u003c/a\u003e, a supplement produced with financial support from \u003ca href=\"https://www.astellas.com/en/innovation/primary-focus-blindness-regeneration\" data-track=\"click\" data-label=\"https://www.astellas.com/en/innovation/primary-focus-blindness-regeneration\" data-track-category=\"body text link\"\u003eAstellas Pharma\u003c/a\u003e. \u003ci\u003eNature\u003c/i\u003e maintains full independence in all editorial decisions related to the content. \u003ca href=\"https://partnerships.nature.com/commercial-content-at-nature-research/\" data-track=\"click\" data-label=\"https://partnerships.nature.com/commercial-content-at-nature-research/\" data-track-category=\"body text link\"\u003eAbout this content\u003c/a\u003e.\u003c/p\u003e\u003c/div\u003e\n\n            \n            \n\n            \n                \u003ch2 id=\"related-articles\"\u003eRelated Articles\u003c/h2\u003e\n                \n    \u003cul\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d41586-025-00654-7\" data-track=\"click\" data-track-label=\"related article (rank:0)\"\u003e\n                        \n                            \u003cimg loading=\"lazy\" src=\"https://media.nature.com/lw100/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709308.jpg\" alt=\"\"/\u003e\n                        \n                        Eye problems cloud NASA’s vision of Mars\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d41586-025-00655-6\" data-track=\"click\" data-track-label=\"related article (rank:1)\"\u003e\n                        \n                            \u003cimg loading=\"lazy\" src=\"https://media.nature.com/lw100/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709306.jpg\" alt=\"\"/\u003e\n                        \n                        How can treatment for eye disease be made easier?\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d41586-025-00656-5\" data-track=\"click\" data-track-label=\"related article (rank:2)\"\u003e\n                        \n                            \u003cimg loading=\"lazy\" src=\"https://media.nature.com/lw100/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709304.jpg\" alt=\"\"/\u003e\n                        \n                        Restoring vision with optogenetics\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d41586-025-00657-4\" data-track=\"click\" data-track-label=\"related article (rank:3)\"\u003e\n                        \n                            \u003cimg loading=\"lazy\" src=\"https://media.nature.com/lw100/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709472.jpg\" alt=\"\"/\u003e\n                        \n                        Human echolocation can be taught\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d41586-025-00658-3\" data-track=\"click\" data-track-label=\"related article (rank:4)\"\u003e\n                        \n                            \u003cimg loading=\"lazy\" src=\"https://media.nature.com/lw100/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709310.jpg\" alt=\"\"/\u003e\n                        \n                        Artificial intelligence could boost eye care in low-income countries\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d41586-025-00659-2\" data-track=\"click\" data-track-label=\"related article (rank:5)\"\u003e\n                        \n                            \u003cimg loading=\"lazy\" src=\"https://media.nature.com/lw100/magazine-assets/d41586-025-00653-8/d41586-025-00653-8_50709476.jpg\" alt=\"\"/\u003e\n                        \n                        The search for solutions to geographic atrophy of the retina\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n            \u003cli\u003e\n                \u003cp\u003e\n                    \u003ca href=\"https://www.nature.com/articles/d42473-024-00257-2\" data-track=\"click\" data-track-label=\"related article (rank:6)\"\u003e\n                        \n                        Sponsor feature: The hunt for cell and gene therapies for eye diseases\n                    \u003c/a\u003e\n                \u003c/p\u003e\n            \u003c/li\u003e\n        \n    \u003c/ul\u003e\n\n            \n\n            \n                \u003ch2 id=\"subjects\"\u003eSubjects\u003c/h2\u003e\n                \n    \n\n            \u003csection data-component-latest-content=\"true\" data-track=\"in-view\" data-track-action=\"in-view\" data-track-category=\"latest content\" data-track-label=\"visible\"\u003e\n    \u003ch2 id=\"tablist-heading\"\u003eLatest on:\u003c/h2\u003e\n    \n\u003c/section\u003e\n\n\n\n\n            \n\n        \n            \n                    \u003c/article\u003e\n                \u003c/main\u003e\n            \n        \n\n        \n\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "7 min read",
  "publishedTime": null,
  "modifiedTime": null
}
